Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Broad availability and cost-effectiveness of (99)Mo/(99m)Tc generators worldwide support the use, and thus the development, of novel (99m)Tc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin r...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Doroteja, Janota, Barbara, Hörmann, Anton Amadeus, Sawicka, Agnieszka, Kroselj, Marko, Hubalewska-Dydejczyk, Alicja, Fani, Melpomeni, Mikolajczak, Renata, Kolenc, Petra, Decristoforo, Clemens, Garnuszek, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053408/
https://www.ncbi.nlm.nih.gov/pubmed/36986746
http://dx.doi.org/10.3390/pharmaceutics15030885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053408/
https://www.ncbi.nlm.nih.gov/pubmed/36986746
http://dx.doi.org/10.3390/pharmaceutics15030885

Ejemplares similares